AtriCure (NASDAQ:ATRC – Free Report) had its target price trimmed by Needham & Company LLC from $46.00 to $40.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the medical device company’s stock. Several other brokerages also recently commented on ATRC. StockNews.com downgraded shares of […]
AtriCure (NASDAQ:ATRC – Get Free Report) released its earnings results on Wednesday. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Briefing.com reports. AtriCure had a negative net margin of 8.98% and a negative return on equity of 7.82%. The firm had revenue […]
AtriCure (NASDAQ:ATRC – Get Free Report) had its price objective dropped by analysts at Needham & Company LLC from $46.00 to $40.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price objective points to a potential upside of […]
AtriCure (NASDAQ:ATRC – Get Free Report) had its target price cut by Canaccord Genuity Group from $57.00 to $49.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 134.56% from the stock’s […]
AtriCure (NASDAQ:ATRC – Get Free Report) had its price target decreased by research analysts at JPMorgan Chase & Co. from $42.00 to $34.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential […]